TetraScience and Databricks Join Forces To Transform Scientific Research, Development, Manufacturing, and Quality Control in Life Sciences
BOSTON & SAN FRANCISCO, May 20th, 2024 - TetraScience and Databricks today announced a strategic partnership dedicated to helping life sciences organizations harness Scientific AI to bring more effective and safer therapies to market faster and less expensively.
The life sciences industry is racing to unlock data intelligence and harness the value of AI. Companies want to use their massive data sets and ever-cheaper computational resources but are blocked by more than 10 million silos of unstructured and vendor-specific proprietary data, which inhibit AI.
This partnership rapidly accelerates the Scientific AI revolution by re-platforming and engineering this data to enable the large-scale production of AI-native scientific data across the entire value chain, supporting a growing suite of next-generation lab data management solutions, scientific use cases, and AI-based scientific outcomes.
Scientific use cases already enabled by the partnership include generative AI for data analysis in cell therapy research, a lead clone selection assistant that reduces clone selection time by up to 80%, and digital QC analytics for method performance trending that reduces out-of-specification (OOS) events by up to 75%. Future use cases in the roadmap include predicting IC50 for drug candidates to speed up safety testing by at least 25%, speeding up purification process development through advanced visualizations of process and analytical data, and predicting optimal cell culture conditions to reduce bioprocess development times by up to 80%. This puts the power of AI into the hands of scientists to augment their daily work.
Continue to read.
